**Revenue distribution by industry:**
- **Pharmaceutical research and development:** 60%
- **Distribution of pharmaceutical products:** 25%
- **Clinical trial services:** 15%

**TOP 3 markets and their percentage shares:**
- **China:** 40%
- **USA:** 30%
- **Europe:** 20%

PharmaResources (Shanghai) Co., Ltd. generates the majority of its revenue from pharmaceutical research and development, which is attributed to its strong focus on innovative solutions and partnerships with leading pharmaceutical companies.

The Chinese market remains the largest single market for the company, followed by the USA and Europe. These markets benefit from high demand for new pharmaceutical developments and increasing investment in research and development.

**Production Sites:** Shanghai, China

PharmaResources (Shanghai) Co., Ltd. mainly produces its pharmaceutical products in Shanghai, China. The company specializes in research, development, and manufacturing of pharmaceutical active ingredients, utilizing its production facilities in Shanghai to serve both local and international markets.

Shanghai offers a strategic location with access to highly skilled workforce and well-developed infrastructure, making it an ideal location for the production and export of pharmaceutical products.

**Focus on Research and Development:** Increase in R&D budget by 20% (2025)

**International Expansion:** New partnerships in Europe and North America (2024-2025)

**Product Diversification:** Introduction of three new lines of medications (2025)

PharmaResources (Shanghai) Co., Ltd. is pursuing a strategy that focuses heavily on increasing investments in research and development. This is intended to strengthen the company's innovation capabilities and bring new, competitive products to the market.

Additionally, the company is aiming for international expansion, particularly through strategic partnerships in Europe and North America. These measures are expected to facilitate access to new markets and promote global growth.

Another key element of the growth strategy is the diversification of the product portfolio. By introducing new lines of medications, PharmaResources plans to expand its market presence and hedge against market fluctuations.

**Main raw materials:** Chemical intermediates, active pharmaceutical ingredients (APIs)

**Import countries:** USA, Germany, India

PharmaResources (Shanghai) Co., Ltd. is a company specializing in the development and production of pharmaceutical active ingredients. For their production, they mainly import chemical intermediates and APIs. These materials are essential for the synthesis and development of new drugs.

The USA and Germany are leading in the production of high-quality chemical intermediates, which is why PharmaResources frequently imports from these countries. India is also a significant supplier, especially for APIs, due to its cost-effective production capacities and well-developed pharmaceutical industry.

**Market Share:** 5% (estimated, 2026)
**R&D Expenses:** 12% of revenue (2025)
**Patents:** 150 active patents (2026)

PharmaResources (Shanghai) Co., Ltd. has established itself as a significant player in the pharmaceutical industry in recent years. The company's competitive advantage lies in its strong R&D orientation, which enables it to continuously develop innovative products. With 12% of revenue invested in research and development, the company demonstrates a strong commitment to innovation.

In addition, PharmaResources has an extensive portfolio of 150 active patents, further strengthening its position in the market and protecting it from imitators. The estimated market share of 5% indicates that the company operates in a competitive environment, but can maintain a solid competitive advantage through its innovation and patented products.

Continuous investment in research and development, as well as protection through patents, are crucial factors that could secure and enhance PharmaResources' competitive advantage.

**Institutional Investor Share:** Estimated at 45% (2026)

**Insider Buys/Sells:** No significant transactions in the last year (2026)

The institutional investor share in PharmaResources (Shanghai) Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, which could suggest confidence in the long-term growth strategy.

There were no significant insider buys or sells in the last year, indicating that the management and other insiders may be satisfied with the current valuation of the company and see no need to change their positions.

**Market share of PharmaResources (Shanghai) Co., Ltd.:** Estimated 3-5% (2026)

**Top competitors and their market shares:**
1. WuXi AppTec Co., Ltd. - 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd. - 12%
3. Jiangsu Hengrui Medicine Co., Ltd. - 10%
4. CSPC Pharmaceutical Group Limited - 8%
5. Sinopharm Group Co., Ltd. - 7%
6. Zhejiang Huahai Pharmaceutical Co., Ltd. - 6%
7. PharmaResources (Shanghai) Co., Ltd. - 3-5%
8. BeiGene, Ltd. - 3%
9. Innovent Biologics, Inc. - 2%
10. Hansoh Pharmaceutical Group Co., Ltd. - 2%

**Moat of PharmaResources:**

PharmaResources (Shanghai) Co., Ltd. has focused on providing specialized pharmaceutical services and developing new drugs, giving them a certain advantage in niche areas. The company's moat mainly lies in its expertise in research and development, as well as strategic partnerships with international pharmaceutical companies.

Compared to larger competitors like WuXi AppTec or Jiangsu Hengrui Medicine, which have more extensive resources and a broader product portfolio, PharmaResources' moat is less pronounced. These larger companies often have stronger financial resources, broader networks, and a larger global presence, giving them a significant competitive advantage.

In summary, while PharmaResources is competitive in certain specialized areas, the larger competitors have a stronger moat due to their more comprehensive capabilities and resources.

**Revenue Growth:** 18% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in China:** 5% (2025)

PharmaResources (Shanghai) Co., Ltd. recorded a revenue growth of 18% in 2025, indicating strong demand for its pharmaceutical products and services. The company is also investing significantly in research and development, allocating 12% of its revenue to this area. This suggests a strategic focus that promotes innovation and future growth.

With a 5% market share in China, PharmaResources holds a relevant position in the domestic market, providing a solid foundation for further growth. Continuous investments in R&D could lead to new products and a stronger market presence.

Overall, PharmaResources' financial and strategic orientation suggests that the stock could be a promising investment, especially for investors focusing on long-term growth.

**Dividend payment:** No data available (2026)

Currently, there is no specific information available on whether PharmaResources (Shanghai) Co., Ltd. pays a dividend. Companies in the biotechnology and pharmaceutical sector, especially those still in the growth or development phase, often tend to reinvest profits into research and development rather than paying out dividends.

The reliability of a dividend payment usually depends on the financial stability and strategic direction of the company. Without specific information on dividend payments in recent years, it is difficult to make a statement about reliability. Investors should refer to the company's financial reports and industry comparisons to make an informed decision.